cysteine has been researched along with carbidopa in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S; Jimbow, K; Miura, T | 1 |
| Muhlack, S; Müller, T | 2 |
| Mueller, BK; Muhlack, S; Müller, T; Trommer, I | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cysteine and carbidopa
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for cysteine and carbidopa
| Article | Year |
|---|---|
Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Drug Combinations; Female; GPI-Linked Proteins; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Pilot Projects | 2016 |
3 other study(ies) available for cysteine and carbidopa
| Article | Year |
|---|---|
The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its n-acetyl derivative.
Topics: Animals; Antineoplastic Agents; Carbidopa; Cell Division; Cysteamine; Cysteine; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Kinetics; Levodopa; Melanoma, Experimental; Mice; Mice, Inbred Strains; Monophenol Monooxygenase; Neoplasm Transplantation; Phenols; Substrate Specificity | 1990 |
Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Cysteine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Chromatography, Reverse-Phase; Cysteine; Dipeptides; Drug Delivery Systems; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2014 |